{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:19:30Z","timestamp":1791425970730,"version":"4.3.3"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Yellow fever virus (YFV) causes 30,000 deaths worldwide, despite the availability of a vaccine. There are no approved antiviral therapies for the treatment of YFV disease in humans, and, therefore, these studies were designed to investigate the anti-YFV properties of T-1106, a substituted pyrazine, in a hamster model of YFV disease. Intraperitoneal (i.p.) treatment with 100 mg\/kg of body weight\/day of T-1106 starting 4 h prior to virus inoculation and continuing twice daily through 7 days post-virus inoculation (dpi) resulted in significantly improved survival, alanine aminotransferase levels in the serum, weight gain, and mean day to death. Virus titer in the liver at 4 dpi was significantly reduced in treated animals, as determined by both quantitative real-time PCR and infectious cell culture assay. No toxicity (weight loss or mortality) was observed at a dose of 100 mg\/kg\/day in sham-infected control animals. The observed minimal effective dose of T-1106 was 32 mg\/kg\/day administered either by oral or i.p. treatment. Therapeutic treatment was effective in significantly improving survival when T-1106 was administered beginning as late as 4 days after virus challenge with twice-daily treatment for 8 days at a dose of 100 mg\/kg\/day. With favorable safety, bioavailability, and postviral challenge treatment efficacy, T-1106 was effective in the treatment of disease in hamsters infected with YFV and should be further studied for potential use as a therapy for human YFV disease.<\/jats:p>","DOI":"10.1128\/aac.01494-06","type":"journal-article","created":{"date-parts":[[2007,4,10]],"date-time":"2007-04-10T00:34:03Z","timestamp":1176165243000},"page":"1962-1966","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":45,"title":["Activity of T-1106 in a Hamster Model of Yellow Fever Virus Infection"],"prefix":"10.1128","volume":"51","author":[{"given":"Justin G.","family":"Julander","sequence":"first","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, Utah 84322-5600"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Toyama Chemical Company, Ltd., 3-2-5 Nishishinjuku, Shinjuku-ku, Tokyo 187-0023, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"Shafer","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, Utah 84322-5600"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Sidwell","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, Utah 84322-5600"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"647","volume":"38","year":"1988","unstructured":"Arroyo, J. I., S. A. Apperson, C. B. Cropp, B. J. Marafino, Jr., T. P. Monath, R. B. Tesh, R. E. Shope, and M. A. Garcia-Blanco. 1988. Effect of human gamma interferon on yellow fever virus infection. Am. J. Trop. Med. Hyg.38:647-650.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.12.001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.977-981.2002"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.981-986.2005"},{"key":"e_1_3_2_6_2","first-page":"27","year":"2004","unstructured":"Furuta, Y., K. Takahashi, M. Maekawa, H. Maegawa, H. Egawa, and N. Terashima. 2004. T-1106, a novel pyrazine nucleoside, hepatitis C virus polymerase inhibitor, abstr. F-487, p. 27. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother.","journal-title":"T-1106, a novel pyrazine nucleoside, hepatitis C virus polymerase inhibitor"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.08.008"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/516111"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.4.4.553"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.4.1932-1943.2002"},{"key":"e_1_3_2_11_2","first-page":"S3","volume":"12","year":"2005","unstructured":"Petersen, L. R., and A. A. Marfin. 2005. Shifting epidemiology of Flaviviridae. J. Travel Med.12(Suppl. 1):S3-S11.","journal-title":"J. Travel Med."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.09.058"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2004.71.306"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2006.74.1084"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01051-06"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/am.22.5.797-801.1971"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/320199"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/10408360490497474"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/320200"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01494-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01494-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:25:44Z","timestamp":1645471544000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01494-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1128\/AAC.01494-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.01494-06","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"2006-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}